Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03386721 · ClinicalTrials.gov registry record · Phase 2
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT03386721 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 256 participants.
The verdict
NCT03386721, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors. Currently the focus is on participants with Head and Neck, oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.
Interventions
- DRUG Gemcitabine
- DRUG Vinorelbine
- DRUG Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
- DRUG simlukafusp alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03386721
The ClinicalTrials.gov registry entry for NCT03386721 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT03386721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03386721 about?
NCT03386721 is a clinical study titled "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors". This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors. Currently the focus is on participants with Head and Neck, oesophageal and cervical ca...
What is the current status of trial NCT03386721?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2018-02-19. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT03386721?
The interventions under investigation include: Gemcitabine (DRUG), Vinorelbine (DRUG), Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody (DRUG), simlukafusp alfa (DRUG).
Who is sponsoring clinical trial NCT03386721?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.